MKL001 & MKL002 Pipeline Overview: Treatment of PTSD

 

MiHKAL is currently developing the lead candidates MKL001 and MKL002, two undisclosed prodrugs with the specific aim of addressing Post-Traumatic Stress Disorder (PTSD). Currently in the preclinical phase, MKL001 and MKL002 represent a promising advancement in the field of mental health therapeutics.

As MKL001 and MKL002 progress through the preclinical phase, rigorous testing and validation processes are underway to ensure safety, efficacy, and a profound understanding of the compound's mechanism of action. 

​

Looking ahead, as either MKL001 or MKL002 goes in to clinical phase, the clinical trials will provide valuable insights into the compound's effectiveness in real-world scenarios, bringing us one step closer to offering a transformative solution for individuals grappling with the effects of PTSD. With our candidates, we represent a pioneering approach to address the complexities of PTSD.

​